According to the European Medicine Agency, a" biosimilar" is a biological medicinal product
that contains a version of the active substance of an original biological medicinal product …

Background Darunavir/cobicistat (DRV/COB) is the first fixed combination inhibitor of
protease. Both are metabolised by the cytochrome CYP3A4, the reason why they are …

Biosimilares, el camino ha comenzado Page 1 Farm Hosp. 2015;39(2):114-117 ARTÍCULO DE
OPINIÓN Biosimilares, el camino ha comenzado Alba Martos-Rosa1, Juan Enrique …

Background and importance Antimicrobial resistance is the ability of microorganisms to
evade the effect of antibiotics. The use and abuse of these drugs has increased, as well as …

Background and importance Shortening the duration of antibiotic treatment is one of the
cornerstones to reduce antibiotic pressure and, therefore, the appearance of antimicrobial …

Background Short Bowel Syndrome (SBS) requires comprehensive nutritional control.
Today's personal media available to healthcare systems do not allow daily monitoring of …

Background Currently, drugs for HIV treatment have an important financial impact in our
hospital Pharmacy Department. Protease Inhibitor (PI) monotherapy is a useful tool that can …

Discussion Our patient was treated with SIM/SOF/RBV and had undetectable viral load at
the end of treatment and 12 weeks after treatment completion (SVR12). Currently, clinical …

Objective: To analyse anticholinergic agent consumption in HIV patients 50 years or older; to
determine anticholinergic risk using the Anticholinergic Cognitive Burden Scale (ACB) and …

Background Omalizumab is indicated as add-on treatment to improve asthma control in
patients with severe persistent allergic asthma who have reduced lung function as well as …